Related Experiment Video
Updated: Jun 22, 2026

Modifications of the Langendorff Method for Simultaneous Isolation of Atrial and Ventricular Myocytes from Adult Mice
Published on: May 13, 2021
Milrinone inhibits hypoxia or hydrogen dioxide-induced persistent sodium current in ventricular myocytes
Jie Zheng1, Jihua Ma, Peihua Zhang
1Cardio-Electrophysiological Research Laboratory, Medical College, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Abstract:
Much evidence indicates that increased persistent sodium current (I(Na.P)) is associated with cellular calcium overload and I(Na.P) is considered to be a potential target for therapeutic intervention in ischaemia and heart failure. By inhibiting type III phosphodiesterase, milrinone increases intracellular cyclic adenosine monophosphate (cAMP), with a positive inotropic effect. However, the effect of milrinone on increased I(Na.P) under pathological conditions remains unknown. Accordingly, we investigated the effect of milrinone on increased I(Na.P) induced by hypoxia or hydrogen dioxide in guinea pig ventricular myocytes. While milrinone (0.01 mM or 0.1mM) or cAMP (0.1 mM) decreased I(Na.P) respectively in control condition, application of 1 microM H-89, a selective cAMP-dependant protein kinase inhibitor, prevented the effect of 0.1mM milrinone in control condition. Milrinone (0.1 mM) reduced the increased I(Na.P) induced by hypoxia. Furthermore, 0.01 mM or 0.1mM milrinone reduced the enhanced I(Na.P) induced by 0.3 mM hydrogen peroxide. In addition, 0.01 mM or 0.1 mM milrinone shortened action potential duration at 90% repolarization (APD(90)). Bath application of 0.3 mM hydrogen dioxide markedly prolonged APD(90), while 2 microM tetrodotoxin (TTX) reversed the prolonged APD(90). In the other two groups, 0.01 mM or 0.1 mM milrinone shortened the prolonged APD(90) induced by 0.3 mM hydrogen peroxide, ultimately 2 microM TTX causing a further decurtation of APD(90). These findings demonstrate that milrinone inhibited I(Na.P) under normal condition, hypoxia or hydrogen dioxide-induced I(Na.P), and the APD(90) prolonged by hydrogen dioxide-induced I(Na.P) in ventricular myocytes, which is associated with the mechanism of milrinone increasing intracellular cAMP.
Insights
Milrinone effectively reduces persistent sodium current (I(Na.P)) in heart cells, even under conditions like hypoxia or hydrogen peroxide exposure. This action, linked to increased cyclic adenosine monophosphate (cAMP), may offer therapeutic benefits for heart conditions.
Area of Science:
- Cardiology
- Molecular Pharmacology
- Cell Physiology
Background:
- Increased persistent sodium current (I(Na.P)) is linked to cellular calcium overload.
- I(Na.P) is a potential therapeutic target for ischemia and heart failure.
- Milrinone, a phosphodiesterase inhibitor, increases cyclic adenosine monophosphate (cAMP) and has a positive inotropic effect.
Purpose of the Study:
- To investigate the effect of milrinone on I(Na.P) under pathological conditions.
- To determine if milrinone affects I(Na.P) enhanced by hypoxia or hydrogen peroxide in guinea pig ventricular myocytes.
Main Methods:
- Electrophysiological recordings of I(Na.P) in guinea pig ventricular myocytes.
- Application of milrinone, cAMP, H-89 (a protein kinase inhibitor), hypoxia, and hydrogen peroxide.
- Measurement of action potential duration at 90% repolarization (APD(90)).
Main Results:
- Milrinone and cAMP decreased I(Na.P) in control conditions; H-89 blocked milrinone's effect.
- Milrinone reduced hypoxia-induced and hydrogen peroxide-enhanced I(Na.P).
- Milrinone shortened APD(90) prolonged by hydrogen peroxide, an effect partially reversed by tetrodotoxin (TTX).
Conclusions:
- Milrinone inhibits I(Na.P) under normal, hypoxic, and hydrogen peroxide-induced conditions.
- Milrinone's inhibition of I(Na.P) and shortening of APD(90) in pathological states are associated with increased intracellular cAMP.
- These findings suggest milrinone's potential therapeutic role in conditions involving I(Na.P) dysfunction.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Vasodilators
